[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"electroacupuncture\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:electroacupuncture":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,24,0,[8,47,67,90,118,143,168,196,220,247,274,298,323,344,371,392,414,438,459,481,511,538,559,579],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100644315","electroacupuncture-for-preventing-chemotherapy-induced-peripheral-neuropathy-in-patients-with-early-stage-cancer-100644315",false,"NCT07663396","Electroacupuncture for Preventing Chemotherapy-Induced Peripheral Neuropathy in Patients With Early-stage Cancer","Electroacupuncture for Preventing Chemotherapy-Induced Peripheral Neuropathy in Patients With Early-stage Cancer: A Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Pathological and imaging examinations confirmed the diagnosis of early-stage cancer(I-III stage), including: breast cancer, gastric cancer, intestinal cancer, non-small cell lung cancer or ovarian cancer.\n* Eastern Cooperative Oncology Group Performance Status of 0 or 1.\n* Scheduled to receive chemotherapy containing a taxane, utidelone, or oxaliplatin, with no significant pre-existing neurological symptoms prior to chemotherapy. Specific regimens include: Colorectal cancer: Oxaliplatin-containing regimen. Gastric cancer: Oxaliplatin-containing or taxane-containing regimen. Breast cancer: Taxane-containing or utidelone-containing regimen. Non small cell lung cancer or Ovarian cancer: Taxane-containing regimen.\n* No history of acupuncture treatment within one month prior to study initiation.\n* Adequate major organ function, meeting the following laboratory criteria: Hematology: Absolute neutrophil count ≥ 1.5 × 10\\^9\u002FL; Platelet count ≥ 100 × 10\\^9\u002FL; White blood cell count 3.5 - 9.5 × 10\\^9\u002FL; Hemoglobin ≥ 100 g\u002FL. Hepatic Function: Total bilirubin ≤ 1.5 × upper limit of normal; Aspartate aminotransferase and alanine aminotransferase ≤ 3 × ULN; Serum bilirubin concentration \\\u003C 1.5 mg\u002FdL; Serum albumin \\> 2.5 g\u002FdL. Renal Function: Serum creatinine ≤ 1.5 × ULN, OR calculated creatinine clearance ≥ 50 mL\u002Fmin (using the Cockcroft-Gault formula). Coagulation: International normalized ratio ≤ 1.5, AND activated partial thromboplastin time ≤ 1.5 × ULN.\n* Willing to receive acupuncture intervention and undergo subsequent follow-up assessments.\n* Voluntarily agree to participate in the study and sign an informed consent form.\n\nExclusion Criteria:\n\n* Patients with advanced cancer.\n* Pre-existing peripheral neuropathy prior to the initiation of chemotherapy.\n* Severe impairment of major organ function, rendering the patient unable to tolerate standard-dose chemotherapy.\n* Presence of active skin infection or other conditions unsuitable for acupuncture treatment.\n* Coexisting underlying diseases associated with peripheral neuropathy, such as diabetes mellitus, Guillain-Barré syndrome, or chronic inflammatory demyelinating polyradiculoneuropathy.\n* Current use of medications for neuropathic pain (e.g., gabapentin, pregabalin).\n* Pregnant or lactating patients.\n* Presence of dermatological conditions, as assessed by the clinician, that may interfere with the study procedures or outcomes.\n* Patients with active brain metastases.\n* Patients with a history of implanted cardiac pacemakers or defibrillators, or a history of epilepsy.","ALL","18 Years",{"count":19,"type":20},278,"ESTIMATED","INTERVENTIONAL",[23],"NA","This randomized controlled clinical trial aims to clarify the clinical efficacy and safety of electroacupuncture combined with thumbtack needle for the prevention of chemotherapy-induced peripheral neuropathy(CIPN), and to provide high-level evidence-based medicine for the prevention of CIPN in patients with early stage cancer. At the same time, the effects of electroacupuncture on the median nerve, tibial nerve, sural nerve sensory conduction velocity and sensory nerve action potential, as well as on the median nerve and tibial nerve motor conduction velocity will be analyzed.",[26,27,28,29],"Electroacupuncture","Chemotherapy","Peripheral Neuropathy","Early Stage Cancer",[31,27,32,33],"electroacupuncture","Peripheral neuropathy","early stage cancer","NOT_YET_RECRUITING","2026-06-17",{"date":37,"type":38},"2026-06-23","ACTUAL",{"date":40,"type":20},"2026-05-25",{"date":42,"type":20},"2029-07-31",{"name":44,"class":45},"Affiliated Hospital of Qinghai University","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":56,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":65,"leadSponsor":66,"locationsCount":46},"100642496","electroacupuncture-for-preventing-chemotherapy-induced-peripheral-neuropathy-in-patients-with-advanced-cancer-100642496","NCT07644533","Electroacupuncture for Preventing Chemotherapy-Induced Peripheral Neuropathy in Patients With Advanced Cancer","Electroacupuncture for Preventing Chemotherapy-Induced Peripheral Neuropathy in Patients With Advanced Cancer: A Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Pathological and imaging examinations confirmed the diagnosis of advanced cancer(IV stage), including: breast cancer, gastric cancer, intestinal cancer, non-small cell lung cancer or ovarian cancer;\n* Eastern Cooperative Oncology Group Performance Status of 0 or 1.\n* Scheduled to receive chemotherapy containing a taxane, utidelone, or oxaliplatin, with no significant pre-existing neurological symptoms prior to chemotherapy. Specific regimens include: Colorectal cancer: Oxaliplatin-containing regimen. Gastric cancer: Oxaliplatin-containing or taxane-containing regimen. Breast cancer: Taxane-containing or utidelone-containing regimen. NSCLC or Ovarian cancer: Taxane-containing regimen.\n* No history of acupuncture treatment within one month prior to study initiation.\n* Adequate major organ function, meeting the following laboratory criteria: Hematology: Absolute neutrophil count ≥ 1.5 × 10\\^9\u002FL; Platelet count ≥ 100 × 10\\^9\u002FL; White blood cell count 3.5 - 9.5 × 10\\^9\u002FL; Hemoglobin ≥ 100 g\u002FL. Hepatic Function: Total bilirubin ≤ 1.5 × upper limit of normal (ULN); Aspartate aminotransferase and alanine aminotransferase ≤ 3 × ULN; Serum bilirubin concentration \\\u003C 1.5 mg\u002FdL; Serum albumin \\> 2.5 g\u002FdL. Renal Function: Serum creatinine ≤ 1.5 × ULN, OR calculated creatinine clearance ≥ 50 mL\u002Fmin (using the Cockcroft-Gault formula). Coagulation: International normalized ratio ≤ 1.5, AND activated partial thromboplastin time ≤ 1.5 × ULN.\n* Willing to receive acupuncture intervention and undergo subsequent follow-up assessments.\n* Voluntarily agree to participate in the study and sign an informed consent form.\n\nExclusion Criteria:\n\n* Patients with early-stage cancer.\n* Pre-existing peripheral neuropathy prior to the initiation of chemotherapy.\n* Severe impairment of major organ function, rendering the patient unable to tolerate standard-dose chemotherapy.\n* Presence of active skin infection or other conditions unsuitable for acupuncture treatment.\n* Coexisting underlying diseases associated with peripheral neuropathy, such as diabetes mellitus, Guillain-Barré syndrome, or chronic inflammatory demyelinating polyradiculoneuropathy.\n* Current use of medications for neuropathic pain (e.g., gabapentin, pregabalin).\n* Pregnant or lactating patients.\n* Presence of dermatological conditions, as assessed by the clinician, that may interfere with the study procedures or outcomes.\n* Patients with active brain metastases.\n* Patients with a history of implanted cardiac pacemakers or defibrillators, or a history of epilepsy.",{"count":55,"type":20},264,[23],"This randomized controlled clinical trial aims to clarify the clinical efficacy and safety of electroacupuncture combined with thumbtack needle for the prevention of chemotherapy-induced peripheral neuropathy(CIPN), and to provide high-level evidence-based medicine for the prevention of CIPN in patients with advanced cancer. At the same time, the effects of electroacupuncture on the median nerve, tibial nerve, sural nerve sensory conduction velocity and sensory nerve action potential, as well as on the median nerve and tibial nerve motor conduction velocity will be analyzed.",[26,27,59,28],"Advanced Cancer",[27,59,32,26],"2026-06-10",{"date":63,"type":38},"2026-06-12",{"date":40,"type":20},{"date":42,"type":20},{"name":44,"class":45},{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":74,"enrollmentInfo":75,"targetDuration":4,"studyType":21,"phases":77,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":4},"100635364","effect-of-low-frequency-electroacupuncture-on-diabetic-peripheral-neuropathy-100635364","NCT07551726","Effect of Low-Frequency Electroacupuncture on Diabetic Peripheral Neuropathy","Effect of Low-Frequency Electroacupuncture on Diabetic Peripheral Neuropathy: Study Protocol for a Randomized Controlled Trial","Inclusion Criteria:\n\n\\- 1.Aged 18-70 years, with no restriction on disease duration or sex. 2.Met the diagnostic criteria for DPN, evidenced by: decreased NCV on lower-limb electroneurography, and\u002For persistent pain and\u002For sensory abnormalities in the limbs (at least in both lower limbs), with diminished ankle reflex (unilateral or bilateral) and reduced vibration sense, and a Toronto Clinical Scoring System (TCSS) score ≥ 6.\n\n3.Able to communicate effectively. 4.No severe systemic medical conditions (e.g., cardiac, cerebral, hepatic, or renal disorders), severe psychiatric illnesses, or cognitive impairment.\n\n5.Mentally competent, voluntarily agree to participate in the study, and provide written informed consent.\n\nExclusion Criteria:\n\n* 1.Peripheral neuropathy due to other etiologies (e.g., hypothyroidism, alcohol, medications, hereditary causes), presence of limb ulcers or gangrene, or a history of skin ulceration or poorly healing lesions.\n\n  2.Severe comorbid conditions, including renal, cardiovascular, cerebrovascular, pulmonary, or hepatic diseases, infectious diseases, malignancies, or severe psychiatric disorders.\n\n  3.History of knee\u002Fhip replacement surgery or lower limb fracture within the past 3 months, or any other condition that could interfere with the assessment of neuropathy.\n\n  4.Received acupuncture or moxibustion treatment specifically for DPN within the past 3 months.\n\n  5.Concurrent participation in another interventional clinical trial. 6.Women who are planning pregnancy, are pregnant, or are lactating. 7.Unwillingness to be randomized to either the waitlist (WL) or EA group. 8.Chronic abuse of opioids, analgesics, illicit drugs, or alcohol.","70 Years",{"count":76,"type":20},92,[23],"Diabetic peripheral neuropathy (DPN) is a common and disabling complication of diabetes. Many patients experience pain, numbness, and impaired quality of life, while currently available treatments may have limited benefit or cause adverse effects. Electroacupuncture (EA) may provide a safe, non-pharmacological treatment option, but further clinical evidence is needed.\n\nThe purpose of this study is to evaluate the efficacy and potential mechanisms of low-frequency (2 Hz) electroacupuncture in patients with DPN. In this prospective, randomized, sham-controlled trial, participants will be assigned to either a verum 2 Hz EA group or a sham EA group. The study will assess nerve conduction velocity, pain intensity, serum neurotrophic factors and inflammatory cytokines, and quality of life.\n\nThis study is intended to provide clinical evidence on the use of low-frequency EA for DPN and to examine whether its effects are related to neurotrophic and inflammatory pathways.",[80,26],"Diabetic Peripheral Neuropathy (DPN)","2026-04-20",{"date":83,"type":38},"2026-04-27",{"date":85,"type":20},"2026-04-26",{"date":87,"type":20},"2027-12-31",{"name":89,"class":45},"The First Affiliated Hospital of Zhejiang Chinese Medical University",{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":96,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":98,"minAge":17,"maxAge":99,"enrollmentInfo":100,"targetDuration":4,"studyType":21,"phases":102,"briefSummary":103,"conditions":104,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":117},"100631989","electroacupuncture-for-the-prevention-of-recurrent-lower-urinary-tract-infection-in-women-100631989","NCT07507851","Electroacupuncture for the Prevention of Recurrent Lower Urinary Tract Infection in Women","A Randomized Controlled Trial of Electroacupuncture for the Prevention of Recurrent Lower Urinary Tract Infection in Women","rLUTI","Inclusion Criteria:\n\n1. Female patients aged 18-75 years;\n2. Meeting the diagnostic criteria for recurrent lower urinary tract infections;\n3. No acute lower urinary tract infections at enrollment;\n4. Voluntary participation in this trial and signed informed consent. Only patients who meet all the above inclusion criteria can be enrolled in the study.\n\nExclusion Criteria:\n\n1. Currently receiving prophylactic antibiotics for lower urinary tract infection;\n2. Abnormal urinary tract anatomy (e.g., urinary calculi);\n3. Complicated or neurogenic genitourinary disorders, such as spinal cord injury, cauda equina injury, active pelvic inflammatory disease, active vaginitis, overactive bladder, interstitial cystitis;\n4. Requiring urinary catheterization;\n5. HIV infection, long-term use of immunosuppressants, infection with multidrug-resistant organisms, or uncontrolled diabetes mellitus;\n6. Pelvic organ prolapses of grade 2 or above;\n7. Post-void residual urine volume \\> 100 ml measured by B-ultrasound;\n8. Lactating, pregnant, or planning to conceive within the next 6 months;\n9. Implantation of a cardiac pacemaker;\n10. Malignant tumor; severe cardiac, pulmonary, cerebral, hepatic, renal, or hematological diseases, mental illness, or significant cognitive impairment;\n11. Previous history of electroacupuncture treatment;\n12. Subjects with potential poor compliance (e.g., living far from the hospital). Patients meeting any of the above exclusion criteria shall not be enrolled in the study.","FEMALE","75 Years",{"count":101,"type":20},312,[23],"The goal of this clinical trial is to evaluate if electroacupuncture works to prevent recurrent lower urinary tract infections in female patients. It will also learn about the safety of electroacupuncture. The main questions it aims to answer are:\n\n1. Does electroacupuncture reduce the attacks of acute recurrent urinary tract infections in women?\n2. What medical problems do participants have when taking electroacupuncture?\n\nResearchers will compare electroacupuncture to sham electroacupuncture to assess if electroacupuncture works to prevent recurrent lower urinary tract infections.\n\nParticipants will:\n\n1. Take electroacupuncture or sham electroacupuncture for 30 minutes per session over a 6-month period. During the first month, treatment was administered 3 times weekly (once every other day); the second month, 2 times weekly (once every 2-3 days); and the 3-6 month, once monthly.\n2. Visit the hospital at the end of the 1st, 2nd, 3rd, and 6th months for follow-up evaluations.\n3. Keep a diary of their symptoms and the number of times they use an antibiotic.",[105,106,26,107],"Urinary Tract Infections","Recurrent","Randomized Controlled Trial (RCT)","2026-03-30",{"date":110,"type":38},"2026-04-02",{"date":112,"type":20},"2026-04",{"date":114,"type":20},"2029-03",{"name":116,"class":45},"Yanjun Zhang, Baoyan Liu",2,{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":122,"acronym":4,"eligibilityCriteria":123,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":124,"enrollmentInfo":125,"targetDuration":4,"studyType":21,"phases":127,"briefSummary":128,"conditions":129,"keywords":133,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":46},"100631137","effects-of-different-frequency-electroacupuncture-on-suprahyoid-muscles-in-post-stroke-dysphagia-efficacy-and-neural-networks-100631137","NCT07496762","Effects of Different-Frequency Electroacupuncture on Suprahyoid Muscles in Post-Stroke Dysphagia: Efficacy and Neural Networks","Inclusion Criteria:\n\n* Diagnosis: Patients diagnosed with cerebral infarction confirmed by CT or MRI.\n* Dysphagia Screening: Presence of varying degrees of dysphagia as screened by the Water Swallow Test (WST).\n* Clinical Status: Conscious and stable vital signs, with the ability to cooperate with the treatment.\n* Age: Aged between 18 and 80 years.\n* Consent: Signed informed consent form obtained from the patient or their legal representative.\n\nExclusion Criteria:\n\n* Dysphagia Etiology: Patients with dysphagia caused by etiologies other than cerebral infarction.\n* MRI Contraindications: Patients with metal implants or pacemakers in the body (contraindications for MRI).\n* Bleeding Risk: Patients with bleeding tendencies or coagulation disorders.\n* Blood Pressure: Patients with uncontrolled hypertension (systolic blood pressure \\> 180 mmHg or diastolic blood pressure \\> 120 mmHg).\n* Organ Failure: Patients with severe failure of vital organs (e.g., heart, liver, or kidney failure).\n* Disease Severity: Patients with critical or life-threatening stroke conditions.\n* Cooperation: Patients unable to cooperate with the treatment due to severe cognitive impairment, aphasia, or other reasons.","80 Years",{"count":126,"type":20},90,[23],"This randomized controlled study in patients with post-stroke dysphagia aims to determine the optimal stimulation frequency of electroacupuncture of the suprahyoid muscles and to elucidate the underlying neural mechanisms. Participants will be assigned to low-frequency (2 Hz), medium-frequency (50 Hz), or high-frequency (100 Hz) electroacupuncture groups. Therapeutic efficacy will be assessed using the Kubota water-drinking test, videofluoroscopic swallowing study (VFSS), and ultrasonography to identify the optimal frequency. In parallel, diffusion tensor imaging (DTI) will be used to evaluate changes in fiber connectivity between swallowing-related cortical regions (bilateral precentral gyrus, insula, supramarginal gyrus, and frontal lobe) and the medullary nucleus tractus solitarius, thereby exploring neural network remodeling and providing mechanistic evidence to inform clinical practice.",[130,131,132,26],"Stroke Sequelae","Deglutition Disorders","Acupuncture Therapy",[130,131,132,26],"2026-03-23",{"date":136,"type":38},"2026-03-27",{"date":138,"type":20},"2026-04-21",{"date":140,"type":20},"2028-12-21",{"name":142,"class":45},"Kaili Chen",{"id":144,"slug":145,"hasResults":11,"nctId":146,"briefTitle":147,"officialTitle":148,"acronym":4,"eligibilityCriteria":149,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":124,"enrollmentInfo":150,"targetDuration":4,"studyType":21,"phases":152,"briefSummary":153,"conditions":154,"keywords":156,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":165,"locationsCount":167},"100631123","efficacy-evaluation-of-electroacupuncture-in-the-treatment-of-functional-dyspepsia-100631123","NCT07496580","Efficacy Evaluation of Electroacupuncture in the Treatment of Functional Dyspepsia","Efficacy Evaluation of Electroacupuncture in the Treatment of Functional Dyspepsia: A Multicenter Clinical Trial Study","Inclusion Criteria:\n\n* Participants who meet the Rome IV diagnostic criteria for functional dyspepsia (FD).\n* Age 18 to 80 years, male or female.\n* Chinese patients with a normal upper gastrointestinal endoscopy within the past 1 year, or judged by a gastroenterologist with more than 3 years of clinical experience to have no structural disease that explains the symptoms.\n* Willing and able to provide written informed consent and comply with study procedures.\n\nExclusion Criteria:\n\n* Functional dyspepsia symptoms caused by severe or malignant diseases (e.g., liver cirrhosis, heart failure, or gastrointestinal tumors).\n* Helicobacter pylori infection, defined as a positive urea breath test or positive Hp test on endoscopy.\n* History of gastrointestinal surgery (except minimally invasive procedures such as laparoscopy).\n* Presence of a permanent or temporary cardiac pacemaker or use of external\u002Ftemporary pacing support.\n* Use of medications that may affect dyspepsia symptoms within 2 weeks prior to enrollment, including antisecretory drugs, antacids, prokinetic agents, digestive enzymes, nonsteroidal anti-inflammatory drugs, antidepressants, or traditional Chinese medicine for FD.\n* Conditions that may make participation difficult, such as severe mental or physical illness, dementia, or illiteracy.\n* Severe coagulation disorders.\n* Acupuncture treatment for gastrointestinal diseases within the past 1 month.\n* Participation in another clinical trial within the past 2 months.\n* Drug abuse or alcohol abuse.\n* Pregnant or breastfeeding women.",{"count":151,"type":20},105,[23],"Functional dyspepsia (FD) is a common disorder that causes stomach discomfort, such as fullness or pain after eating, without any visible structural disease. Acupuncture is often used to manage these symptoms. This study aims to evaluate the safety and effectiveness of electroacupuncture-a form of acupuncture that uses gentle electrical stimulation-for treating functional dyspepsia. Specifically, the trial will compare the benefits of applying electroacupuncture to points on the abdomen (local points) versus points on the arms and legs (distal points), alongside a control group receiving a sham (inactive) treatment. The goal is to determine the most effective acupuncture strategy for improving patients' digestive symptoms and overall quality of life.",[155,26],"Functional Dyspepsia",[157,31,158,159],"functional dyspepsia","Local Acupoints","Distal Acupoints","2026-03-22",{"date":136,"type":38},{"date":163,"type":20},"2026-03-01",{"date":87,"type":20},{"name":166,"class":45},"The Third Affiliated hospital of Zhejiang Chinese Medical University",4,{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":172,"acronym":4,"eligibilityCriteria":173,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":99,"enrollmentInfo":174,"targetDuration":4,"studyType":21,"phases":176,"briefSummary":177,"conditions":178,"keywords":182,"overallStatus":186,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":46},"100562319","study-on-the-impact-of-electroacupuncture-combined-with-self-acupressure-on-the-quality-of-life-of-patients-with-early-stage-breast-cancer-undergoing-chemotherapy-100562319","NCT06601621","Study on the Impact of Electroacupuncture Combined With Self-Acupressure on the Quality of Life of Patients With Early-Stage Breast Cancer Undergoing Chemotherapy","Inclusion Criteria:\n\n1. Aged 18 years or older and aged 75 years or younger, inclusive. with an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2;\n2. Patients who have not received prior chemotherapy and are scheduled to receive at least 4 cycles of adjuvant or neoadjuvant chemotherapy or combination targeted therapy;\n3. Normal organ function with platelets ≥ 100\\*10\\^9\u002F L, hemoglobin ≥ 90 g\u002FL, serum creatinine ≤ 1.5 mg\u002Fdl (133 mmol\u002FL), or creatinine clearance ≥ 60 ml\u002Fmin, total bilirubin ≤ 1.5 times the upper limit of normal (ULN), alanine aminotransferase ≤ 2.5 times ULN, and aspartate aminotransferase ≤ 2.5 times ULN;\n4. Premenopausal women need appropriate contraception;\n5. Ability to understand the study well and complete the study questionnaire.\n\nExclusion Criteria:\n\n1. Patients with needle phobia or allergy to stainless steel needles; and\n2. Current diagnosis of mental illness (e.g., major depression, obsessive-compulsive disorder, or schizophrenia);\n3. History of autoimmune diseases, blood disorders, or organ transplantation, or long-term use of hormones or immunosuppressants;\n4. Comorbid bleeding disorders or thyroid dysfunction;\n5. Implantation of a pacemaker; pregnancy or breastfeeding;\n6. A plan for adjuvant radiotherapy in the upcoming chemotherapy cycle;\n7. Current active infection;\n8. Acupuncture treatment within the last four weeks;\n9. Patients who are allergic to the drugs used;\n10. Use of other Traditional Chinese Medicine (TCM) techniques such as Chinese herbs in the next chemotherapy cycle.",{"count":175,"type":20},192,[23],"This randomized controlled clinical trial aims to evaluate the effect of electroacupuncture combined with self-acupressure on the quality of life of early-stage breast cancer patients receiving chemotherapy.",[26,179,180,181,27],"Quality of Life (QOL)","Acupressure","Breast Cancer",[31,183,184,185],"self-acupressure","Quality of life (QOL)","breast cancer","RECRUITING","2026-02-11",{"date":189,"type":38},"2026-02-12",{"date":191,"type":38},"2024-10-19",{"date":193,"type":20},"2026-04-30",{"name":195,"class":45},"Jiuda Zhao",{"id":197,"slug":198,"hasResults":11,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":4,"eligibilityCriteria":202,"healthyVolunteers":203,"sex":98,"minAge":204,"maxAge":74,"enrollmentInfo":205,"targetDuration":4,"studyType":21,"phases":207,"briefSummary":208,"conditions":209,"keywords":4,"overallStatus":186,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":218,"locationsCount":46},"100565520","electroacupuncture-regulation-of-immune-cells-in-herpes-zoster-100565520","NCT06643247","Electroacupuncture Regulation of Immune Cells in Herpes Zoster","The Regulatory Mechanisms of Electroacupuncture Intervention on Immune Cells in Herpes Zoster","Inclusion Criteria for HZ:\n\n* Meets HZ diagnostic criteria;\n* Female, aged between 50 and 70 years;\n* Disease duration ≤7 days, with no prior antiviral, analgesic, or other treatments;\n* Herpetic lesions limited to the trunk, within 1 to 3 dermatomes;\n* Willing to participate in the trial and has signed the informed consent form.\n\nInclusion Criteria for HC:\n\n* No history of HZ or major cardiovascular, respiratory, digestive, urinary, hematologic, endocrine, or neurological diseases;\n* Age-matched female HC volunteers for the HZ group;\n* Clear consciousness and ability to communicate normally;\n* Fully understands the study protocol, demonstrates good compliance, and is willing to cooperate with the study;\n* Has signed a written informed consent form.\n\nExclusion Criteria:\n\n* Special types of herpes zoster, including ophthalmic, otic, visceral, meningeal herpes zoster, and zoster sine herpete;\n* Women who are planning to conceive, pregnant, or breastfeeding;\n* Patients with severe primary diseases of the circulatory, respiratory, or endocrine systems, or systemic failure;\n* Patients with bleeding tendencies;\n* Use of corticosteroids or immunosuppressants within the past month.",true,"50 Years",{"count":206,"type":20},8,[23],"Herpes Zoster (HZ), caused by the Varicella-Zoster Virus (VZV), is a common infection characterized by localized pain and blistering, with higher incidence in females. HZ affects patients' physical health, mental well-being, and quality of life. The immune system is critical in HZ pathogenesis. Studies show acupuncture relieves pain, modulates immunity, and may lower postherpetic neuralgia (PHN) risk. However, evidence is limited on whether electroacupuncture (EA) alleviates HZ by modulating immune cells. Using mass cytometry (CyTOF), this study will analyze peripheral immune cell changes pre- and post-EA to explore its regulatory effects on HZ immunity. This study will recruit HZ patients and healthy controls (HC), dividing patients into medication-only and medication+EA groups to assess EA's potential immunomodulatory effects in HZ treatment.",[210,26,211],"Herpes Zoster","Immune","2026-02-01",{"date":214,"type":38},"2026-02-03",{"date":216,"type":38},"2024-11-11",{"date":87,"type":20},{"name":219,"class":45},"First People's Hospital of Hangzhou",{"id":221,"slug":222,"hasResults":11,"nctId":223,"briefTitle":224,"officialTitle":225,"acronym":4,"eligibilityCriteria":226,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":99,"enrollmentInfo":227,"targetDuration":4,"studyType":21,"phases":229,"briefSummary":231,"conditions":232,"keywords":235,"overallStatus":186,"whyStopped":4,"lastUpdateSubmitDate":239,"lastUpdatePostDateStruct":240,"startDateStruct":242,"completionDateStruct":244,"leadSponsor":246,"locationsCount":46},"100589323","phase-3-electroacupuncture-for-chemotherapy-induced-gi-symptom-clusters-in-breast-cancer-100589323","NCT06952920","Electroacupuncture for Chemotherapy-Induced GI Symptom Clusters in Breast Cancer","Electroacupuncture for Managing Chemotherapy-Induced Gastrointestinal Symptom Clusters in Patients With Breast Cancer","Inclusion Criteria:\n\n1. Pathologically confirmed stage I-III breast cancer;\n2. An Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0-1;\n3. Age between 18 and 75 years;\n4. Scheduled to receive highly emetogenic chemotherapy regimens, such as EC (epirubicin + cyclophosphamide) or platinum-based regimens, during the first cycle of neoadjuvant\u002Fadjuvant chemotherapy;\n5. No prior acupuncture treatment within one month before enrollment;\n6. Voluntary participation in the study with written informed consent obtained; (7) An expected survival of at least 3 months;\n\n(8) Premenopausal women must agree to use contraception during the study period; (9) Adequate bone marrow, liver, and kidney function as defined by standard laboratory criteria.\n\nExclusion Criteria:\n\n1. Patients with advanced-stage cancer;\n2. Those undergoing concurrent chemoradiotherapy;\n3. Individuals with severe impairment of vital organ function who cannot tolerate standard-dose chemotherapy;\n4. Patients with contraindications to acupuncture, such as active skin infections;\n5. Those with digestive system diseases accompanied by nausea and vomiting symptoms that may interfere with accurate assessment;\n6. Patients with a history of xerostomia;\n7. Individuals with known allergies to the study drugs;\n8. Pregnant or breastfeeding patients;\n9. Individuals currently using medications with antiemetic activity, such as 5-HT3 receptor antagonists, corticosteroids (except at physiological doses), dopamine receptor antagonists, minor tranquilizers, antihistamines, and benzodiazepines (except for nighttime sedation);\n10. Patients with seizure disorders requiring anticonvulsant therapy;\n11. Those receiving thiazides as chronic antipsychotic medications;\n12. Those with known arrhythmias, uncontrolled congestive heart failure, or acute myocardial infarction.",{"count":228,"type":20},388,[230],"PHASE3","This study aims to elucidate the therapeutic efficacy of electroacupuncture in managing chemotherapy-induced gastrointestinal symptom clusters through clinical research. Building upon this foundation, multi-omics analyses will be conducted to investigate the regulatory effects and underlying mechanisms of electroacupuncture on gastrointestinal symptoms. Ultimately, genomic studies will be performed to further clarify the key targets of electroacupuncture intervention, thereby providing high-level evidence-based medical support and theoretical foundations for optimizing electroacupuncture strategies in addressing chemotherapy-induced gastrointestinal symptoms in patients with cancer.",[233,26,234],"Standard Quadruple Antiemetic Therapy","Chemotherapy-induced Gastrointestinal Symptom Cluster",[185,236,237,31,238],"chemotherapy","standard quadruple antiemetic therapy","chemotherapy-induced gastrointestinal symptom cluster","2025-12-08",{"date":241,"type":38},"2025-12-15",{"date":243,"type":38},"2025-08-21",{"date":245,"type":20},"2028-06-30",{"name":195,"class":45},{"id":248,"slug":249,"hasResults":11,"nctId":250,"briefTitle":251,"officialTitle":252,"acronym":4,"eligibilityCriteria":253,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":254,"targetDuration":4,"studyType":21,"phases":256,"briefSummary":257,"conditions":258,"keywords":262,"overallStatus":186,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":267,"startDateStruct":269,"completionDateStruct":271,"leadSponsor":272,"locationsCount":46},"100611367","electroacupuncture-combined-with-pd-1-inhibitor-for-ecog2-advanced-nsclc-100611367","NCT07239661","Electroacupuncture Combined With PD-1 Inhibitor for ECOG2 Advanced NSCLC","The Clinical Efficacy of Electroacupuncture Combined With PD-1 Inhibitor in the Treatment of ECOG2 Advanced Non-small Cell Lung Cancer","Inclusion Criteria:\n\n* Patients diagnosed with stage ⅢB-Ⅳ non-small cell lung cancer (NSCLC) confirmed by pathological or cytological examination;\n* Patients with negative driver gene mutations, excluding those harboring EGFR mutations, ALK rearrangements, or other common driver gene alterations as determined by genetic testing or other molecular biological methods;\n* An Eastern Cooperative Oncology Group (ECOG) performance status score of 2;\n* A programmed death-ligand 1 (PD-L1) tumor proportion score (TPS) ≥ 1%;\n* An expected survival time of more than 3 months, as assessed by the clinician based on the patient's overall condition, tumor progression, and response to treatment;\n* Patients with good treatment compliance who provided written informed consent, confirming their understanding of and willingness to undergo treatment and follow-up according to the study protocol.\n\nExclusion Criteria:\n\n* Patients with a history or concurrent diagnosis of other malignant tumors within the past five years;\n* Patients with severe organ impairment or serious comorbidities, such as cardiac dysfunction (New York Heart Association \\[NYHA\\] class Ⅲ-Ⅳ), hepatic or renal insufficiency, as determined by standard clinical examinations including liver and kidney function tests and electrocardiography;\n* Patients with untreated central nervous system (CNS) metastases were excluded; eligible patients were required to have stable disease confirmed by imaging after receiving at least one systemic or surgical treatment;\n* Patients with psychiatric disorders, including schizophrenia or bipolar disorder, particularly those requiring pharmacologic treatment;\n* Patients with a history of multiple drug allergies, an allergic predisposition, or a history of severe allergic reactions such as anaphylactic shock or allergic rash;\n* Subjects with active autoimmune or infectious diseases, including but not limited to chronic viral hepatitis, active pulmonary tuberculosis, or other infections or autoimmune disorders deemed by clinicians to potentially affect the study;\n* Female patients who were pregnant or lactating.",{"count":255,"type":20},120,[23],"The aim of this study was to systematically evaluate the clinical efficacy and safety of electroacupuncture (EA) combined with PD-1 inhibitors in patients with advanced non-small cell lung cancer (NSCLC) who have an ECOG performance status of 2 through a multicenter, randomized, sham-controlled clinical trial. The core scientific question addressed in this study was whether EA combined with standard immunotherapy could further improve progression-free survival (PFS), immune function, and quality of life in these patients. Patients meeting the inclusion criteria were randomly assigned in a 1:1 ratio to receive EA plus a PD-1 inhibitor (trial group) or sham EA plus a PD-1 inhibitor (control group) through a computerized randomization system. PD-1 inhibitors were administered every 21 days for four to six cycles, followed by maintenance therapy according to each patient's condition. EA intervention was initiated on the first day of each immunotherapy cycle and administered once daily for five sessions per cycle, continuing for four to six cycles. The primary endpoint was progression-free survival (PFS). The secondary endpoints included objective response rate (ORR), overall survival (OS), first-line treatment completion rate, quality of life as assessed by the EORTC QLQ-C30 scale, traditional Chinese medicine (TCM) syndrome score, immune function index, and incidence of adverse events according to CTCAE 5.0 criteria. In addition, peripheral blood was collected from patients at baseline for non-coding RNA sequencing, and differentially expressed genes were identified through bioinformatics analysis to determine potential molecular biomarkers associated with the synergistic effects of EA, thereby providing a basis for accurately identifying patients likely to benefit from EA therapy.",[259,26,260,261],"Non-Small Cell Lung Cancer","PD-1 Inhibitors","ECOG PS 2 Points",[31,263,264,259,265],"Immunotherapy","immune checkpoint inhibitor","ECOG PS 2 points","2025-11-16",{"date":268,"type":38},"2025-11-20",{"date":270,"type":20},"2025-11-30",{"date":87,"type":20},{"name":273,"class":45},"Kong Fanming",{"id":275,"slug":276,"hasResults":11,"nctId":277,"briefTitle":278,"officialTitle":279,"acronym":4,"eligibilityCriteria":280,"healthyVolunteers":11,"sex":98,"minAge":17,"maxAge":204,"enrollmentInfo":281,"targetDuration":4,"studyType":21,"phases":283,"briefSummary":284,"conditions":285,"keywords":288,"overallStatus":186,"whyStopped":4,"lastUpdateSubmitDate":289,"lastUpdatePostDateStruct":290,"startDateStruct":292,"completionDateStruct":294,"leadSponsor":296,"locationsCount":46},"100544108","electroacupuncture-for-dysmenorrhea-secondary-to-adenomyosis-100544108","NCT06364592","Electroacupuncture for Dysmenorrhea Secondary to Adenomyosis","Effect of Electroacupuncture for Dysmenorrhea Secondary to Adenomyosis: an Exploratory Pilot Study","Inclusion Criteria:\n\n* Meeting the diagnosis criteria of dysmenorrhea secondary to adenomyosis.\n* Female patients aged between 18 and 50.\n* Dysmenorrhea lasting for 3 consecutive menstrual cycles or more.\n* At least three consecutive menstrual cycles with an interval of 24 to 38 days, differing by less than 7 days, and menstrual periods lasting 2 to 8 days before screening.\n* At least 2 days of worst pain score ≥4 on Numerical Rating Scale during the screening period.\n* Having not used medications, other than rescue medicine, or therapies for dysmenorrhea secondary to adenomyosis for at least 1 month before randomization, and consenting not to use throughout the process of the research.\n* Volunteering to participate the trial and signing written informed consent.\n\nExclusion Criteria:\n\n* Diagnosed with Endometriosis or having a history of endometriosis-related surgery\n* Currently taking hormonal medications, including: a.use of GnRH agonists within 6 months before the screening period; b. use of progestins or danazol and other long-acting hormones within 3 months before the screening period; c. use of oral contraceptive-like short-acting hormones within one month before the screening period;\n* Having clinically significant gynecologic condition such as clinically significant endometrial pathology, persistent complex ovarian cyst larger than 3 cm or simple ovarian cyst larger than 5 cm, or single fibroid 4 cm or larger or more than 4 fibroids measuring at least 2 cm or symptomatic submucosal fibroid of any size.\n* having an IUD.\n* HB \\\u003C 90G\u002FL.\n* Having any other chronic pain syndrome that required chronic analgesic or other chronic therapy.\n* Having a current history of undiagnosed abnormal genital bleeding.\n* Malignant tumors (including the reproductive system and other systems).\n* Combined with severe diseases in the cardiac, respiratory, renal, liver, and hematopoietic systems, psychiatric disorder and\u002For cognitive disorders.\n* Pregnant, breast feeding, planning a pregnancy within the next 7 months.",{"count":282,"type":20},30,[23],"The aim of this study is to preliminarily evaluate the is to assess the effects and safety of electroacupuncture for moderate to severe dysmenorrhea secondary to adenomyosis.",[286,287,26],"Dysmenorrhea","Adenomyosis",[286,287,26],"2025-08-01",{"date":291,"type":38},"2025-08-06",{"date":293,"type":38},"2024-07-21",{"date":295,"type":20},"2026-12-31",{"name":297,"class":45},"Guang'anmen Hospital of China Academy of Chinese Medical Sciences",{"id":299,"slug":300,"hasResults":11,"nctId":301,"briefTitle":302,"officialTitle":303,"acronym":4,"eligibilityCriteria":304,"healthyVolunteers":11,"sex":16,"minAge":305,"maxAge":306,"enrollmentInfo":307,"targetDuration":4,"studyType":21,"phases":308,"briefSummary":309,"conditions":310,"keywords":312,"overallStatus":186,"whyStopped":4,"lastUpdateSubmitDate":315,"lastUpdatePostDateStruct":316,"startDateStruct":318,"completionDateStruct":320,"leadSponsor":322,"locationsCount":46},"100599577","electroacupuncture-combined-with-pd-1-inhibitor-for-elderly-patients-with-advanced-nsclc-100599577","NCT07086300","Electroacupuncture Combined With PD-1 Inhibitor for Elderly Patients With Advanced NSCLC","Clinical Study of Electroacupuncture Combined With PD-1 Inhibitor Treatment for Elderly Patients With Advanced Non-small Cell Lung Cancer","Inclusion Criteria:\n\n* Patients with stage IIIB-IV non-small cell lung cancer (NSCLC) confirmed by histopathological or cytological diagnosis.\n* Patients with negative driver gene mutations, as determined by genetic testing or other molecular biological methods, to exclude common driver mutations such as EGFR mutations and ALK rearrangements.\n* Patients aged ≥65 years, with consideration for the patients' overall physical condition. Additional assessments will be conducted if there are comorbidities or other factors that may affect their physical status.\n* PD-L1 tumor proportion score (TPS) ≥1%.\n* Estimated survival time \\>3 months, as determined by clinical evaluation based on the patient's overall condition, tumor progression, and response to treatment.\n* ECOG performance status score of 0-2.\n* Patients with good treatment compliance, who are willing to sign an informed consent form, indicating their understanding and agreement to adhere to the study protocol for treatment and follow-up.\n\nExclusion Criteria:\n\n* Patients with a history of or concurrent other malignancies within the past 5 years.\n* Patients with severe organ dysfunction or other serious comorbidities, such as heart failure (NYHA Class III-IV), hepatic or renal insufficiency, as assessed by routine examinations including liver function tests, renal function tests, and electrocardiograms.\n* Patients with untreated central nervous system metastases. Only those who have undergone at least one course of systemic or surgical treatment and have been confirmed to have stable disease by imaging studies will be included.\n* Patients with psychiatric disorders, including a history of severe mental illnesses (e.g., schizophrenia, bipolar disorder) that require pharmacological treatment for control.\n* Patients with a history of multiple drug allergies or an allergic constitution, particularly those who have experienced severe allergic reactions such as anaphylactic shock or allergic rashes.\n* Patients with active autoimmune diseases or infectious diseases, including but not limited to active or chronic viral hepatitis, active pulmonary tuberculosis, or other infectious or autoimmune conditions deemed by the clinical investigator to potentially affect the study.\n* Patients who are pregnant or breastfeeding.","65 Years","100 Years",{"count":255,"type":20},[23],"The goal of this clinical trial is to elucidate the clinical efficacy and safety of electroacupuncture combined with PD-1 inhibitor therapy in elderly patients with advanced non-small cell lung cancer (NSCLC) through a multicenter, randomized controlled clinical trial. The main question it aims to answer is: the combination of electroacupuncture and PD-1 inhibitor therapy has demonstrated significant improvements in both clinical efficacy and safety profiles among elderly patients with advanced NSCLC. Researchers will compare a sham electroacupuncture group combined with PD-1 inhibitor therapy (serving as the control group) to see if the intervention group exhibits superior therapeutic efficacy and safety outcomes. Participants will be randomly assigned to one of two groups: an electroacupuncture combined with an immune checkpoint inhibitor group, or a sham electroacupuncture combined with an immune checkpoint inhibitor group. The immune checkpoint inhibitor will be administered on a 21-day cycle, with a total of 4 to 6 treatment cycles, followed by the option for maintenance therapy. Electroacupuncture treatment will commence on the same day as the initiation of the immune checkpoint inhibitor cycle, administered once daily for a total of five sessions per cycle, with 4 to 6 cycles in total. The primary outcome measure is progression-free survival (PFS). Secondary outcomes include objective response rate (ORR), quality of life, immune function, traditional Chinese medicine syndrome scores for lung cancer, and safety parameters. This study aims to establish the efficacy and safety of electroacupuncture combined with PD-1 inhibitors in elderly patients with advanced NSCLC. Additionally, peripheral non-coding RNA will be collected at baseline to analyze differentially expressed genes, thereby identifying molecular predictive biomarkers for patients who may benefit most from this combined treatment approach.",[311,259,260,26],"Elderly Patients (>65 Years)",[31,313,314,263,264],"Elderly patients","non-small cell lung cancer","2025-07-18",{"date":317,"type":38},"2025-07-25",{"date":319,"type":38},"2025-07-08",{"date":321,"type":20},"2028-12-31",{"name":273,"class":45},{"id":324,"slug":325,"hasResults":11,"nctId":326,"briefTitle":327,"officialTitle":328,"acronym":4,"eligibilityCriteria":329,"healthyVolunteers":203,"sex":16,"minAge":17,"maxAge":124,"enrollmentInfo":330,"targetDuration":4,"studyType":21,"phases":332,"briefSummary":333,"conditions":334,"keywords":4,"overallStatus":186,"whyStopped":4,"lastUpdateSubmitDate":336,"lastUpdatePostDateStruct":337,"startDateStruct":339,"completionDateStruct":341,"leadSponsor":343,"locationsCount":46},"100577759","efficacy-and-central-mechanisms-of-electroacupuncture-for-medication-overuse-headache-100577759","NCT06802471","Efficacy and Central Mechanisms of Electroacupuncture for Medication Overuse Headache","Efficacy and Central Mechanism of Electroacupuncture for Medication Overuse Headache: a Multicenter Randomized Controlled Trial","Inclusion Criteria for Patients with MOH:\n\n* Meet the diagnostic criteria of MOH in ICHD-3;\n* A history of migraine (according to ICHD-3 criteria)\u002Ftension headache (TTH) (according to ICHD-3 criteria) for ≥12 months before screening;\n* Patients entered data from the electronic headache diary for at least 24 of the 28 days of the screening period (evidence of good adherence to the electronic headache diary);\n* Prospectively collected data from the electronic headache diary during the screening period met the following criteria: 15 or more headache days per month; Regular overdose of acute or symptomatic headache medications meets the diagnostic criteria for MOH；\n* Headache diagnosed before the age of 50 years;\n* Patients had failed MOH withdrawal treatment (with medical documentation or specific physician confirmation of each treatment) on ≥1 occasions in the previous 3 years; Withdrawal treatment failure is defined as no significant reduction in headache frequency, duration and\u002For severity after withdrawal treatment; Or intolerable withdrawal reactions during withdrawal treatment; Or unable to quit treatment due to safety issues;\n* Aged between 18 and 80 years old;\n* Signed the informed consent and volunteered to participate in the study.\n* Patients who met the above 8 criteria were included in this study.\n\nExclusion Criteria for Patients with MOH:\n\n* Patients had a history or diagnosis of hypotensive headache, continuous hemiplegia, new daily persistent headache, or unusual migraine subtypes, such as hemiplegic migraine (sporadic and familial), ocular tension migraine, migraine with neurologic symptoms that were atypical of migraine aura (diplopia, altered consciousness, or prolonged duration). Other types of primary or secondary headache;\n* The presence of clinically significant pain syndromes that may be confusing (e.g., fibromyalgia, chronic low back pain, complex regional pain syndrome); Acute or active temporomandibular joint disorders;\n* The patient had an uncontrolled and\u002For untreated mental illness (e.g., severe depression and schizophrenia) for at least 6 months prior to the screening visit; Patients with a history of psychosis and\u002For mania within 5 years before screening were excluded;\n* The patient has any other medical condition whose treatment takes precedence over MOH treatment or may interfere with the study treatment or impair compliance with treatment;\n* Taking\u002Fusing medications\u002Fstimulation devices that may affect headache (e.g., beta-blockers (atenolol, propranolol, metoprolol, etc.) due to headache or other reasons within 3 months before or during the screening period; Calcium channel blockers (flunarizine, benzothiazide, etc.); Antidepressants (amitriptyline, venlafaxine, duloxetine, etc.); Antiepileptic drugs (topiramate, sodium valproate, carbamazepine, etc); Angiotensin-receptor blockers (candesartan and lisinopril); Botulinum toxin; Gabapentin; Noninvasive vagus nerve stimulation, transcranial magnetic stimulation, peripheral trigeminal nerve stimulation; Biofeedback, health products; Occipital nerve block, other nerve block; Continuous infusion therapy, steroid reduction; Chiropractic therapy, physical therapy); Or treatment with injections (trigger point injections, extracranial nerve blocks or facet joint injections) on the head, face or neck;\n* The patient has a history of moderate or severe head or neck trauma, or other neurological or systemic diseases (such as epilepsy and dementia) that the researcher believes may affect the central nervous system function;\n* Patients have or have had one or more of the following conditions that were considered in the study to be associated with clinical symptoms: other neurological, pulmonary, hepatic, endocrine, gastrointestinal, hematologic, infectious, immunologic, or ocular conditions;\n* A history of substance or alcohol abuse (according to DSM-5® criteria) within 24 months prior to the screening visit;\n* During the screening or baseline visit, the patient has significant suicide risk (answers \"Yes\" to question 4 or 5 on the C-SSRS suicide ideation section, or answers \"Yes\" to any question regarding suicidal behavior at any time during the study on the C-SSRS);\n* Prophylactic treatment for headache was received 1 month before the screening visit;\n* One month before the screening visit, the patient had participated in a clinical study; Or had taken any medication for headache within the 5 plasma half-lives, whichever was longer, before the screening visit;\n* Severe uncontrolled disease such as cancer, uncontrolled cardiovascular disease, severe hepatic and renal insufficiency, or coagulopathy; Women who are pregnant or preparing to become pregnant;\n* Having known fear of acupuncture or having received acupuncture treatment within 8 weeks before enrollment;\n* In the judgment of the investigators, the patients have diseases or take drugs that may affect the assessment of the safety, tolerability, or efficacy of the trial, or affect the conduct or interpretation of the study.\n* Any one of the above items is excluded.\n\nInclusion Criteria for Patients with episodic migraine(Control group 1):\n\n* According to the ICHD-3 criteria, it met the diagnostic criteria of episodic migraine; With\u002Fwithout tension-type headache;\n* Headache days\u002Fmonth ≤6 days at enrollment;\n* The number of days\u002Fmonth of using analgesics at enrollment was ≤6 days;\n* Age between 18 and 80 years;\n* Be able to fill out a headache diary;\n* No previous history of drug abuse;\n* No obvious comorbidities pain, physical or mental disorders;\n* No alcohol or drug addiction;\n* No pregnancy, breastfeeding, or plans for pregnancy in the next 12 months;\n\nInclusion Criteria for Healthy Participants(Control group 2):\n\n* No headache or headache ≤2 days in the past 12 months at enrollment;\n* No more than 6 days\u002Fmonth of use of analgesics at enrollment;\n* Age between 18 and 80 years;\n* No significant comorbidities pain, physical, or mental disorders;\n* No organic, functional changes or systemic diseases that could cause headache;\n* No history of head or neck trauma;\n* No significant abnormalities in blood routine, biochemical tests, coagulation function, or urine routine in the past 12 months prior to enrollment;\n* No alcohol or drug addiction;\n* No pregnancy, breastfeeding, or plans for pregnancy in the next 12 months.\n\nNonrandomized patients with MOH:\n\n●Participants who meet the MOH diagnostic criteria and fulfill the inclusion\u002Fexclusion criteria but decline randomization will be assigned to the non-randomized electroacupuncture group. These participants will receive electroacupuncture treatment directly, with no restrictions on the number of participants per center.",{"count":331,"type":20},160,[23],"Acupuncture is commonly used for the prevention of migraine and tension-type headaches, and has been found to be effective in reducing both the frequency and severity of these conditions. However, studies on acupuncture for medication overuse headache (MOH) are limited, and current research has not been able to determine whether its efficacy is due to the actual therapeutic effects of acupuncture or psychological benefits. To address this issue, the investigators have designed a clinical trial to evaluate the efficacy of acupuncture for MOH. In addition, the investigators will explore the regulatory effects of electroacupuncture on central mechanisms in MOH and conduct multi-omics analysis.",[335,26],"Medication Overuse Headache","2025-07-13",{"date":338,"type":38},"2025-07-16",{"date":340,"type":38},"2025-02-01",{"date":342,"type":20},"2027-06",{"name":297,"class":45},{"id":345,"slug":346,"hasResults":11,"nctId":347,"briefTitle":348,"officialTitle":348,"acronym":4,"eligibilityCriteria":349,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":124,"enrollmentInfo":350,"targetDuration":4,"studyType":21,"phases":352,"briefSummary":353,"conditions":354,"keywords":358,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":362,"lastUpdatePostDateStruct":363,"startDateStruct":365,"completionDateStruct":367,"leadSponsor":369,"locationsCount":46},"100598849","zusanli-st36-electroacupuncture-treatment-for-neoadjuvant-immunotherapy-in-non-small-cell-lung-cancer-100598849","NCT07076836","Zusanli (ST36) Electroacupuncture Treatment for Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer","Inclusion Criteria:\n\n1. Age ≥18 and ≤80 years at the time of written informed consent, of either sex;\n2. Histologically or cytologically confirmed diagnosis of extensive-stage small cell lung cancer (SCLC) or non-small cell lung cancer (NSCLC) receiving neoadjuvant immunotherapy;\n3. Undergoing standard first-line treatment with chemotherapy plus immunotherapy\n4. ECOG performance status score of 0-2;\n5. Life expectancy \\>3 months;\n6. At least one measurable target lesion per RECIST 1.1 criteria:\n7. Tumor lesions with a long axis ≥10 mm on CT scan (slice thickness ≤5 mm);\n8. Lymph node lesions with a short axis ≥10 mm on CT scan;\n9. Previously irradiated or locally treated lesions may be designated as target lesions if documented tumor progression post-treatment.\n10. Adequate major organ function within 14 days prior to randomization, defined by the following laboratory parameters without blood transfusions, growth factors, albumin, or blood products:\n11. Hematological tests: Hemoglobin ≥80 g\u002FL; Absolute neutrophil count \\>1.5×10⁹\u002FL; Platelet count ≥90×10⁹\u002FL;\n12. Biochemical tests: Total bilirubin ≤1.5×ULN (upper limit of normal); ALT\u002FAST ≤2.5×ULN; Serum creatinine ≤1.5×ULN or creatinine clearance ≥50 mL\u002Fmin (Cockcroft-Gault formula);\n13. Coagulation tests: Prothrombin time (PT) and INR ≤1.5×ULN (unless on warfarin anticoagulation);\n14. Cardiac evaluation: Left ventricular ejection fraction (LVEF) ≥50% by Doppler echocardiography.\n15. Voluntary participation with signed informed consent, good compliance, and willingness of the patient and their family to cooperate with survival follow-up.\n\nExclusion Criteria:\n\n1. Pregnant participants;\n2. Post-organ transplant patients;\n3. Patients with uncontrolled diabetes mellitus, severe cardiac, central nervous system, psychiatric disorders, or coagulopathy;\n4. Patients with severe malnutrition;\n5. Patients with implanted cardiac pacemakers;\n6. Patients with bleeding disorders;\n7. Patients with a history of severe allergies or anaphylaxis;\n8. Patients with skin infections, lesions, ulcers, or scars at the ST36 (Zusanli) acupoint site;\n9. Patients with metal allergy, severe needle phobia, or intolerance to electroacupuncture therapy.",{"count":351,"type":20},82,[23],"This study aims to investigate the potential synergistic effects of acupuncture combined with immune checkpoint inhibitors in cancer therapy. Over the past decade, significant progress in cancer immunotherapy has been driven by breakthroughs in understanding immune checkpoint molecules; however, monotherapy with immune checkpoint inhibitors still faces challenges due to low response rates. As a traditional Chinese medical intervention, acupuncture modulates neuro-immune pathways to achieve remote regulation of organ functions, with particular anti-tumor potential observed at the Zusanli (ST36) acupoint-a site located 2 cm below the knee that can be stimulated via electroacupuncture (EA) to improve gastrointestinal function and alleviate inflammation. Preclinical evidence demonstrates that EA suppresses tumor growth in breast cancer models, reduces levels of pro-inflammatory cytokines such as IL-1β and TNF-α, enhances anti-tumor activity of CD8+ T cells and NK cells, and decreases accumulation of immunosuppressive myeloid-derived suppressor cells (MDSCs). Animal studies show that ST36 EA increases key immunomodulatory factors like serum IFN-γ, IL-2, and IL-17, thereby potentiating the efficacy of anti-tumor drugs. Guided by the traditional TCM principle of \"reinforcing healthy qi to consolidate the body's resistance,\" modern clinical applications of EA combined with specific acupoint regimens (e.g., ST36, Sanyinjiao) have effectively alleviated cancer-related pain, chemotherapy-induced side effects, and fatigue. This study will evaluate the safety and immunosensitization effects of ST36 EA combined with PD-1 inhibitors in non-small cell lung cancer patients, employing 1 mA electroacupuncture for 3 consecutive days to activate immune responses. By leveraging acupuncture-induced immune remodeling, this approach aims to provide a novel integrative medicine strategy to overcome resistance to immunotherapy.",[355,356,357,26],"Lung Cancer (NSCLC)","Small Cell Lung Cancer ( SCLC )","Immune Checkpoint Blockade",[359,360,361,31],"lung cancer (NSCLC)","small cell lung cancer (SCLC)","immune checkpoint blockade","2025-07-11",{"date":364,"type":38},"2025-07-22",{"date":366,"type":20},"2025-07-31",{"date":368,"type":20},"2026-06-30",{"name":370,"class":45},"West China Hospital",{"id":372,"slug":373,"hasResults":11,"nctId":374,"briefTitle":375,"officialTitle":376,"acronym":4,"eligibilityCriteria":377,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":124,"enrollmentInfo":378,"targetDuration":4,"studyType":21,"phases":380,"briefSummary":382,"conditions":383,"keywords":4,"overallStatus":186,"whyStopped":4,"lastUpdateSubmitDate":385,"lastUpdatePostDateStruct":386,"startDateStruct":388,"completionDateStruct":390,"leadSponsor":391,"locationsCount":46},"100595582","phase-2-electroacupuncture-combined-with-immune-checkpoint-inhibitors-as-adjuvant-therapy-after-surgery-for-early-stage-non-small-cell-lung-cancer-100595582","NCT07034326","Electroacupuncture Combined With Immune Checkpoint Inhibitors as Adjuvant Therapy After Surgery for Early-stage Non-small Cell Lung Cancer","Observation on the Clinical Efficacy of Electroacupuncture Combined With Immune Checkpoint Inhibitors as Adjuvant Therapy After Surgery for Early-stage Non-small Cell Lung Cancer","Inclusion Criteria:\n\n* (1) Non-tumor patients with stage Ⅱ, ⅢA, ⅢB (N2) non-small cell lung cancer diagnosed by pathology or cytology after surgery; (2) driver mutations negative patients; (3) Postoperative adjuvant chemotherapy was received for 1 to 4 cycles;(4)conforms to two qi syndrome of traditional Chinese medicine syndrome differentiation diagnosis of patients; (5) aged 18 to 80 years old; (6) expected lifetime \\> 6 months; (7) ECOG 0 to 2 points; (8) patients willing to accept this solution treatment, adherence to the good.\n\nExclusion Criteria:\n\n* (1) Patients with other malignant tumors in the past or at the same time within 5 years; (2) has a serious heart, liver and kidney damage, or other serious complications; (3) the R1, R2, need after resection, postoperative adjuvant radiotherapy patients; (4) with mental disorders; (5) has a variety of drug allergy, allergic constitution; (6) in pregnancy or lactation women.",{"count":379,"type":20},405,[381,230],"PHASE2","Postoperative immunoadjuvant therapy has been proven to significantly reduce the risk of recurrence after resectable NSCLC, and has become a new standard of postoperative adjuvant therapy for stage II-III NSCLC. Immunotherapy faces challenges such as immune resistance, heterogeneity of biomarker expression, and limitation of immune-suitable population. How to reduce the rate of recurrence and metastasis after surgery, enhance the therapeutic effect of immunotherapy, and then prolong the survival period and improve the quality of life, has become an urgent problem facing the current clinical. Based on the standards of evidence-based medicine, this study for the first time carried out a large sample, multi-center, randomized parallel controlled clinical study to obtain high-quality clinical evidence of the effectiveness and safety of electro-acupuncture and Zilongjin tablet synergic treatment, and formed a standard treatment plan of traditional Chinese medicine.",[259,26,384],"Immune Checkpoint Inhibitors","2025-06-15",{"date":387,"type":38},"2025-06-24",{"date":389,"type":38},"2025-01-01",{"date":321,"type":20},{"name":273,"class":45},{"id":393,"slug":394,"hasResults":11,"nctId":395,"briefTitle":396,"officialTitle":397,"acronym":4,"eligibilityCriteria":398,"healthyVolunteers":11,"sex":98,"minAge":17,"maxAge":399,"enrollmentInfo":400,"targetDuration":4,"studyType":21,"phases":402,"briefSummary":403,"conditions":404,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":406,"lastUpdatePostDateStruct":407,"startDateStruct":409,"completionDateStruct":411,"leadSponsor":413,"locationsCount":46},"100594782","the-efficacy-and-safety-of-acupuncture-for-prophylaxis-of-menstrually-related-migraine-100594782","NCT07023926","The Efficacy and Safety of Acupuncture for Prophylaxis of Menstrually Related Migraine","The Efficacy and Safety of Acupuncture for Prophylaxis of Menstrually Related Migraine: a Pilot Randomized Controlled Trial","Inclusion Criteria:\n\n1. meet the diagnostic criteria for MRM according to the ICHD-3, with a documented history of MRM for at least 12 months;\n2. have a confirmed diagnosis of migraine by a neurologist;\n3. aged 18-45 years;\n4. have regular menstrual cycles (28 ± 7 days) with menstruation lasting 3-7 days;\n5. have experienced ≥3 headache days during each menstrual cycle (days -2 to +3) and ≥5 total headache days per cycle over the past 3 months and baseline period; migraine attacks must last 4-72 hours without acute medication, or at least 2 hours when treated;\n6. have completed a headache diary during the screening period (covering at least one full menstrual cycle), demonstrating good compliance;\n7. headache diary data during screening period must meet the ICHD-3 criteria for MRM and fulfill criteria (4) and (5);\n8. voluntarily sign the informed consent.\n\nExclusion Criteria:\n\n1. irregular menstrual cycles, defined as cycle length outside the range of 28±7 days or menstruation duration \\\u003C3 days or \\>7 days;\n2. presence of secondary headache disorders, facial neuralgia, or cranial neuralgia;\n3. combined with serious primary diseases such as cardiovascular, hepatic, renal, gastrointestinal, or hematological disorders that may interfere with the treatment protocol, or comorbid neurological conditions such as epilepsy, parkinson's disease, or other central nervous system disorders;\n4. headache symptoms caused by other conditions, such as moderate to severe head or neck trauma, perimenstrual infections, intracranial tumors, intracranial infections, endocrine or metabolic disorders;\n5. receipt of preventive treatment for headache within 1 month prior to the screening visit;\n6. afraid of needles or received acupuncture treatment within 3 months;\n7. unwillingness to undergo the study intervention or failure to sign the informed consent.","45 Years",{"count":401,"type":20},40,[23],"Acupuncture is commonly used for the prevention of migraine and tension-type headaches, and has been found to be effective in reducing both the frequency and severity of these conditions. However, studies on acupuncture for menstrually related migraine (MRM) are limited, and current research has not been able to determine whether its efficacy is due to the actual therapeutic effects of acupuncture or psychological benefits. To address this issue, the investigators have designed a clinical trial to evaluate the efficacy of acupuncture for MRM.",[405,26],"Menstrually Related Migraine","2025-06-14",{"date":408,"type":38},"2025-06-17",{"date":410,"type":20},"2025-07-01",{"date":412,"type":20},"2027-01-31",{"name":297,"class":45},{"id":415,"slug":416,"hasResults":11,"nctId":417,"briefTitle":418,"officialTitle":419,"acronym":4,"eligibilityCriteria":420,"healthyVolunteers":11,"sex":16,"minAge":204,"maxAge":124,"enrollmentInfo":421,"targetDuration":4,"studyType":21,"phases":423,"briefSummary":424,"conditions":425,"keywords":4,"overallStatus":186,"whyStopped":4,"lastUpdateSubmitDate":428,"lastUpdatePostDateStruct":429,"startDateStruct":431,"completionDateStruct":433,"leadSponsor":435,"locationsCount":46},"100548421","the-treatment-of-postherpetic-neuralgia-in-the-head-and-face-with-superficial-needling-combined-with-electroacupuncture-100548421","NCT06420778","The Treatment of Postherpetic Neuralgia in the Head and Face With Superficial Needling Combined With Electroacupuncture","A Randomized Controlled Study on the Treatment of Postherpetic Neuralgia in the Head and Face With Superficial Needling Combined With Electroacupuncture","Inclusion Criteria:\n\nMeet the diagnostic criteria in the 2016 Chinese Expert Consensus on the Diagnosis and Treatment of Postherpetic Neuralgia; Age 50-80 years (including telangiectasia), gender is not limited; Have a history of herpes zoster on the head and face, and the lesions on the head and face have been healed and subsided, and the symptoms of neuralgia lasted ≥1 month after lesions were healed, with baseline scores of ≥4 on the Facial Pain Profile, and abnormal sensation of the skin around the lesions, pain sensitivity; Be conscious and have a clear sense of pain and discriminative ability; Sign the informed consent to participate in this study voluntarily. Only those who satisfy the above 5 items at the same time can be included in this study.\n\nExclusion Criteria:\n\nthose who did not meet the above diagnostic criteria; herpes zoster occurring in the perineum, or special types such as visceral herpes zoster, meningeal herpes zoster, and generalized herpes zoster; those who were taking oral pregabalin at a dose of less than 0.2 g or more than 0.6 g per day before inclusion to relieve analgesia; those who had a serious adverse reaction to pregabalin, were allergic to acupuncture, or belonged to patients who were within the range of contraindications to electro-acupuncture; Combined with severe cardiac, hepatic, renal damage, epilepsy, head injury, or cognitive dysfunction, aphasia, psychiatric disorders, and other major diseases, who are unable to cooperate with the treatment; Combined with poorly controlled hypertension and diabetes mellitus patients; Pregnant or breastfeeding patients;8.Patients who are currently participating in other studies, and who have been enrolled in other clinical trials within the last 3 months. Anyone who meets any of these criteria will be excluded.",{"count":422,"type":20},124,[23],"Based on the inclusion and exclusion criteria, patients with head and face PHN who met the requirements were selected as trial subjects, and the efficacy was clarified in a randomized controlled design trial. The visual analog score VAS was used as the primary evaluation index, and the depression self-assessment scale score , Hamilton depression scale, Pittsburgh sleep quality index scale, and quality of life evaluation scale (SF-36) were used as the secondary evaluation indexes, and oral pregabalin was used as the control group, and the subjects in the pregabalin and the plexus superficial stabbing combined with electroacupuncture groups were observed respectively at the time of Before treatment, immediately after the first treatment, after 2 days of treatment, after 2 weeks of treatment, after 4 weeks of treatment, after 1 month of follow-up after the end of treatment and after 2 months of follow-up after the end of treatment.",[426,26,427],"Postherpetic Neuralgia","Infrared Thermography","2025-04-02",{"date":430,"type":38},"2025-04-06",{"date":432,"type":38},"2024-07-12",{"date":434,"type":20},"2025-12-31",{"name":436,"class":437},"Zhejiang Chinese Medical University","OTHER_GOV",{"id":439,"slug":440,"hasResults":11,"nctId":441,"briefTitle":442,"officialTitle":443,"acronym":4,"eligibilityCriteria":444,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":99,"enrollmentInfo":445,"targetDuration":4,"studyType":21,"phases":446,"briefSummary":447,"conditions":448,"keywords":4,"overallStatus":186,"whyStopped":4,"lastUpdateSubmitDate":451,"lastUpdatePostDateStruct":452,"startDateStruct":454,"completionDateStruct":456,"leadSponsor":457,"locationsCount":46},"100584509","the-treatment-of-moderate-to-severe-allergic-rhinitis-with-electroacupuncture-combined-with-microneedle-knife-100584509","NCT06890260","The Treatment of Moderate to Severe Allergic Rhinitis With Electroacupuncture Combined With Microneedle Knife","A Clinical Randomized Controlled Study of Electroacupuncture Combined With Microneedle Knife in the Treatment of Moderate to Severe Allergic Rhinitis","Inclusion Criteria:\n\n1. Those with clinical and laboratory diagnosis of moderate to severe allergic rhinitis;\n2. Aged ≥18 years and ≤75 years, with no restriction on gender or ethnicity;\n3. Not taking drugs such as antihistamines or nasal steroids within 1 month before enrollment;\n4. Those who voluntarily participated in this study and signed an informed consent form, and who were able to adhere to outpatient treatment for 4 weeks.\n\nExclusion Criteria:\n\n1. Atrophic rhinitis, hypertrophic rhinitis, vasomotor rhinitis, acute and chronic sinusitis, nasal polyps, severe septal deviation, eosinophilia non-allergic rhinitis;\n2. Those with other allergic diseases such as asthma, urticaria, and colds that cause nasal congestion, runny nose, and sneezing;\n3. Those who have serious diseases such as cardiovascular, cerebrovascular, hepatic, renal and hematopoietic systems in combination;\n4. Pregnant or lactating women, psychiatric patients, patients with malignant tumors.",{"count":126,"type":20},[23],"Based on the inclusion and exclusion criteria, patients with allergic rhinitis who meet the requirements are selected as trial subjects, and the efficacy is clarified in a randomized controlled design trial. We will Use the total nasal symptom score as the primary outcome index, serum chemokine, intercellular adhesion molecule-1, eosinophil cationic protein, total non-nasal symptom score, and rhinitis-related quality of life scale as secondary outcome indexes, and oral cetirizine hydrochloride tablets and nasal budesonide spray as the control group, the efficacy of the subjects in the electroacupuncture combined with microneedle knife group and the drug group will be observed respectively before treatment, after 2 weeks of treatment, after 4 weeks, 1 month follow-up after the end of treatment, and 3 months follow-up after the end of treatment. 4 weeks later, 1 month follow-up after the end of treatment and 3 months follow-up after the end of treatment.",[449,26,450],"Allergic Rhinitis (Disorder)","Microneedle Knife","2025-03-27",{"date":453,"type":38},"2025-03-30",{"date":455,"type":20},"2025-04-11",{"date":87,"type":20},{"name":458,"class":45},"Pengfei Qiu",{"id":460,"slug":461,"hasResults":11,"nctId":462,"briefTitle":463,"officialTitle":464,"acronym":4,"eligibilityCriteria":465,"healthyVolunteers":203,"sex":16,"minAge":17,"maxAge":99,"enrollmentInfo":466,"targetDuration":4,"studyType":21,"phases":468,"briefSummary":469,"conditions":470,"keywords":473,"overallStatus":186,"whyStopped":4,"lastUpdateSubmitDate":451,"lastUpdatePostDateStruct":476,"startDateStruct":477,"completionDateStruct":479,"leadSponsor":480,"locationsCount":46},"100531466","phase-3-electroacupuncture-for-the-prevention-of-chemotherapy-induced-nausea-and-vomiting-in-patients-with-breast-cancer-100531466","NCT06200168","Electroacupuncture for the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients With Breast Cancer","A Study on Electroacupuncture Combined With Olanzapine-contained Four-drug Antiemetic Therapy for the Prevention of Highly Emetogenic Chemotherapy-induced Nausea and Vomiting in Patients With Breast Cancer (ECO Study)","Inclusion Criteria:\n\n1. Aged 18 years or older and aged 75 years or younger, of any nationality;\n2. Eastern Cooperative Oncology Group performance status of 0-2;\n3. Patients with breast cancer, with no restrictions on molecular typing; early-stage patients must not have undergone prior chemotherapy, while advanced-stage patients must be candidates for first-line chemotherapy and have declined neoadjuvant or adjuvant chemotherapy for over 3 months. All patients must receive highly emetogenic chemotherapy (HEC) based on anthracycline chemotherapy with cyclophosphamide (EC or AC) or carboplatin (AUC≥4)\u002Fcisplatin;\n4. Predicted life expectancy of ≥3 months;\n5. Adequate bone marrow, kidney, and liver function;\n6. Adequate contraception if premenopausal women;\n7. Written informed consent by the patient before enrolment.\n\nExclusion Criteria:\n\n1. Patients already submitted to chemotherapy;\n2. Is scheduled to receive any non-HEC on Day 1;\n3. Is scheduled to receive any chemotherapy on days 2-4 after HEC;\n4. Received or is scheduled to receive radiation therapy to the abdomen, pelvis, head and neck within 1 week prior to Day 1 or between Days 1 to 5 in cycle 1;\n5. Has symptomatic primary or metastatic symptomatic central nervous system malignancy causing nausea and\u002For vomiting;\n6. Have ongoing emesis or CTCAE grade 2 or greater nausea;\n7. Significant medical or mental conditions;\n8. Any allergies to study drug, antiemetics or dexamethasone;\n9. Significantly abnormal laboratory values (platelets, coagulation indexes, absolute neutrophils, AST, ALT, bilirubin or creatinine);\n10. Patients who are pregnant or breast-feeding;\n11. Inflammatory skin reaction;\n12. Has lymphedema in acupuncture stimulation area;\n13. Patients who are afraid of electroacupuncture stimulation or allergic to stainless steel needles;\n14. Received acupuncture treatments for any conditions less than 4 weeks before HEC;\n15. Currently using drugs with antiemetic activity (e.g., 5-HT3 receptor antagonists, corticosteroids (except when used at physiological doses), dopamine receptor antagonists, minor tranquilizers, antihistamines, and benzodiazepines (except for nocturnal sedation));\n16. Patients with concomitant severe diseases or with a predisposition to emesis such as gastrointestinal obstruction, active peptic ulcer, and hypercalcemia and symptomatic brain metastasis;\n17. Has a convulsive disorder requiring anticonvulsant treatment;\n18. Patients administered thioridazine as a chronic antipsychotic medication (patients are allowed to receive prochlorperazine and other phenothiazines as a rescue antiemetic treatment);\n19. Concurrent treatment with quinolone antibiotics;\n20. Has a history of chronic alcoholism (determined by the investigator);\n21. Known arrhythmias, uncontrolled congestive heart failure, or acute myocardial infarction within the past six months;\n22. Has a history of uncontrolled diabetes (e.g., using insulin or oral hypoglycemic agents).",{"count":467,"type":20},370,[230],"This randomized controlled phase III trial aims to evaluate the use of electroacupuncture in combination with olanzapine-containing standard quadruple antiemetic drugs for the treatment of nausea and vomiting induced by highly emetogenic chemotherapy (HEC) in patients with breast cancer. Furthermore, it will analyze the relationship between single nucleotide polymorphism and electroacupuncture treatment for chemotherapy-induced nausea and vomiting.",[26,471,472],"Olanzapine-contained Four-drug Antiemetic","Nausea and Vomiting",[31,474,475,185,236],"olanzapine-contained four-drug antiemetic","nausea and Vomiting",{"date":428,"type":38},{"date":478,"type":38},"2024-01-16",{"date":295,"type":20},{"name":195,"class":45},{"id":482,"slug":483,"hasResults":11,"nctId":484,"briefTitle":485,"officialTitle":486,"acronym":4,"eligibilityCriteria":487,"healthyVolunteers":203,"sex":16,"minAge":17,"maxAge":488,"enrollmentInfo":489,"targetDuration":4,"studyType":21,"phases":491,"briefSummary":492,"conditions":493,"keywords":498,"overallStatus":186,"whyStopped":4,"lastUpdateSubmitDate":504,"lastUpdatePostDateStruct":505,"startDateStruct":507,"completionDateStruct":509,"leadSponsor":510,"locationsCount":46},"100562361","electroacupuncture-combined-with-self-administered-acupressure-for-the-prevention-of-capecitabine-associated-hand-foot-syndrome-100562361","NCT06602167","Electroacupuncture Combined With Self-administered Acupressure for the Prevention of Capecitabine-Associated Hand-Foot Syndrome","Electroacupuncture Combined With Self-administered Acupressure for the Prevention of Capecitabine-Associated Hand-Foot Syndrome: a Randomized Controlled Trial","Inclusion Criteria:\n\n1. Sign a written informed consent form;\n2. Male or female ≥ 18 years old;\n3. Patients with gastrointestinal cancer or breast cancer who are diagnosed with cancer by pathology will receive capecitabine treatment for the first time according to the label;\n4. The performance status of the Eastern Cancer Collaboration Group is 0-2;\n5. Palliative or adjuvant chemotherapy with capecitabine (combination or monotherapy, minimum daily total dose of capecitabine 2000 mg\u002Fm\\^2);\n6. Expected lifespan ≥ 3 months;\n7. Laboratory requirements: platelet count ≥ 100 × 10\\^9\u002FL, white blood cell count\\>3.0 × 10\\^9\u002FL, hemoglobin ≥ 10.0 g\u002FdL, normal liver and kidney function;\n8. Adequate contraception.\n\nExclusion Criteria:\n\n1. Previous use of capecitabine or liposome doxorubicin or any other tyrosine kinase inhibitor that may induce HFS (such as sorafenib, sunitinib, and apatinib) for chemotherapy;\n2. The initial dose of capecitabine is less than 800mg\u002Fm\\^2;\n3. Radiation therapy or surgery should be performed within 4 weeks before the start of treatment;\n4. Skin diseases that may interfere with clinical trial results;\n5. Known drug\u002Falcohol abuse;\n6. Pregnant women or lactating patients;\n7. Participate in another clinical trial and the patient has received the investigational drug within the last 30 days prior to the start of treatment (i.e. follow-up in the previous trial was not exclusive);\n8. Known patients who are afraid of electroacupuncture stimulation or allergic to stainless steel needles or any component of capecitabine;\n9. Receive any acupuncture and moxibustion treatment ,there is lymphedema in the area stimulated by acupuncture;\n10. Patients with any chemotherapy- or radiotherapy-related toxicities that have not subsided to grade 2 or lower will be excluded, except for stable sensory neuropathy.\n11. Any unresolved skin toxicity caused by previous chemotherapy or radiotherapy, except for hair loss, will also be grounds for exclusion.","85 Years",{"count":490,"type":20},220,[23],"This study hypothesizes that electroacupuncture combined with self-administered acupressure plus doctor-prescribed treatment is effective in preventing Hand-Foot Syndrome (HFS) caused by capecitabine. It aims to explore the effectiveness of this combined approach in preventing HFS in patients with malignant tumors undergoing oral capecitabine treatment. Further exploration of prevention and treatment methods may enhance the quality of life for patients during the treatment process.",[494,495,26,496,181,497],"Capecitabine","Hand-foot Syndrome","Self-administered Acupressure","Gastrointestinal Cancers",[31,499,500,501,502,503],"capecitabine","self-administered acupressure","Hand-foot syndrome","Breast cancer","Gastrointestinal cancers","2024-12-09",{"date":506,"type":38},"2024-12-12",{"date":508,"type":38},"2024-10-08",{"date":87,"type":20},{"name":44,"class":45},{"id":512,"slug":513,"hasResults":11,"nctId":514,"briefTitle":515,"officialTitle":515,"acronym":4,"eligibilityCriteria":516,"healthyVolunteers":203,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":517,"targetDuration":4,"studyType":21,"phases":519,"briefSummary":520,"conditions":521,"keywords":523,"overallStatus":186,"whyStopped":4,"lastUpdateSubmitDate":529,"lastUpdatePostDateStruct":530,"startDateStruct":532,"completionDateStruct":534,"leadSponsor":536,"locationsCount":46},"100536700","electro-acupuncture-to-treat-disorder-of-consciousness-100536700","NCT06268236","Electro-acupuncture to Treat Disorder of Consciousness","Inclusion Criteria:\n\n1. Age ≥ 18 years;\n2. With cerebral damage due to TBI；\n3. Diagnosed with UWS or MCS based on at least two CRS-R assessments;\n4. From 4 to 16 weeks from the onset of brain injury;\n5. Informed consent obtained.\n\nExclusion Criteria:\n\n1. With a history of neurological or psychiatric disorder prior to the brain injury;\n2. With uncontrolled seizures or status epilepticus;\n3. Unstable vital signs and requiring the use of vasoactive agents;\n4. With the use of general anesthetics or central acting sedative;\n5. Without intact skin at acupoints or sham points;\n6. Concomitant medical illness that would interfere with the outcome assessments and\u002For follow-up\n7. Pregnant patients;\n8. Currently participating in other investigational trials;\n9. High likelihood of not adhering to the study treatment or the follow-up regimen",{"count":518,"type":20},50,[23],"With the rapid development of life support technology, more and more people can survive severe brain injury. Some survivors regain consciousness after a period of coma, however, many patients develop prolonged disorders of consciousness (DOC), which poses a therapeutic challenge for clinicians and a heavy burden for their families. The investigators design an Electro-acupuncture to treat disorder of consciousness (AcuDoc) trial with the aim of validating the clinical effect of electroacupuncture in treating DOC and exploring its therapeutic mechanisms by integrating EEG, neuroimaging, evoked potential tests, and behavioral assessments.",[522,26],"Disorder of Consciousness",[524,525,526,527,528],"Acute brain injury","Disorder of consciousness","Electro-acupuncture","Awakening","Brain functional network","2024-09-12",{"date":531,"type":38},"2024-09-19",{"date":533,"type":38},"2024-01-01",{"date":535,"type":20},"2026-01-31",{"name":537,"class":45},"The Second Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine",{"id":539,"slug":540,"hasResults":11,"nctId":541,"briefTitle":542,"officialTitle":543,"acronym":4,"eligibilityCriteria":544,"healthyVolunteers":203,"sex":16,"minAge":17,"maxAge":99,"enrollmentInfo":545,"targetDuration":4,"studyType":21,"phases":546,"briefSummary":547,"conditions":548,"keywords":549,"overallStatus":186,"whyStopped":4,"lastUpdateSubmitDate":550,"lastUpdatePostDateStruct":551,"startDateStruct":553,"completionDateStruct":555,"leadSponsor":557,"locationsCount":46},"100540289","phase-3-electroacupuncture-plus-antiemetic-therapy-for-chemotherapy-induced-nausea-and-vomiting-in-patients-with-breast-cancer-100540289","NCT06314906","Electroacupuncture Plus Antiemetic Therapy for Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer","Combining Electroacupuncture With Antiemetic Therapy for Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer: A Clinical Study","Inclusion Criteria:\n\n1. Patients aged 18 to 75 years, inclusive, from any nationality.\n2. Patients diagnosed with early-stage breast cancer.\n3. Eastern Cooperative Oncology Group performance status ranging from 0 to 2.\n4. All patients must undergo highly emetogenic chemotherapy (HEC).\n5. Adequate organ function.\n6. Adequate contraception required for premenopausal women.\n\nExclusion Criteria:\n\n1. Scheduled to undergo chemotherapy between days 2 to 4 following HEC.\n2. Received or is planned to receive abdominal radiation therapy within 1 week before Day 1 in cycle 1.\n3. Significant medical or psychological conditions.\n4. Presents with symptomatic primary or metastatic central nervous system malignancy causing nausea and\u002For vomiting.\n5. Experiencing ongoing vomiting or nausea of grade 2 or higher according to Common Terminology Criteria for Adverse Events (CTCAE).\n6. Any known allergies to the study drug, antiemetics, or dexamethasone.\n7. Patients who have fear of electroacupuncture stimulation or are allergic to stainless steel needles.\n8. Received acupuncture treatments for any conditions within 8 weeks prior to HEC.",{"count":467,"type":20},[230],"This study explores the effectiveness of combining electroacupuncture with olanzapine-containing four-drug antiemetic therapy to mitigate chemotherapy-induced nausea and vomiting (CINV) in patients with breast cancer. The research aims to assess the adjunctive benefits of electroacupuncture in enhancing the antiemetic effects of conventional medication, particularly in the context of highly emetogenic chemotherapy regimens. By investigating the synergistic potential of these modalities, the study seeks to provide insights into optimizing supportive care strategies for patients with breast cancer undergoing intensive chemotherapy treatment.",[26,471,472],[31,474,475,185,236],"2024-03-19",{"date":552,"type":38},"2024-03-21",{"date":554,"type":38},"2024-03-07",{"date":556,"type":20},"2027-03-31",{"name":558,"class":45},"Feixue Song",{"id":560,"slug":561,"hasResults":11,"nctId":562,"briefTitle":563,"officialTitle":563,"acronym":4,"eligibilityCriteria":564,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":565,"enrollmentInfo":566,"targetDuration":4,"studyType":21,"phases":568,"briefSummary":569,"conditions":570,"keywords":4,"overallStatus":186,"whyStopped":4,"lastUpdateSubmitDate":571,"lastUpdatePostDateStruct":572,"startDateStruct":574,"completionDateStruct":576,"leadSponsor":578,"locationsCount":46},"100530143","clinical-evaluation-of-surrounding-electroacupuncture-in-the-treatment-of-acute-lateral-ankle-sprain-100530143","NCT06182943","Clinical Evaluation of Surrounding Electroacupuncture in the Treatment of Acute Lateral Ankle Sprain","Inclusion Criteria:\n\n* Meets the diagnostic criteria for a grade I or II injury;\n* Onset time≤48h;\n* The patient aged between18 and 60, gender is not limited;\n* The skin of the ankle joint on the affected side is intact, without breakage or ulceration;\n\nExclusion Criteria:\n\n* Combined with ankle fracture;\n* Grade III injury or complete ligament rupture;\n* Those who cannot comply with the treatment program. Those with keloid, localized combination of other skin diseases, and those who are not suitable for electroacupuncture treatment;\n* Those with serious cardiovascular, cerebrovascular, hepatic, renal, hematopoietic system or systemic failure, connective tissue disease, hemophilia, diabetes mellitus, malignant tumors, and those who are prone to bleeding tendency.","60 Years",{"count":567,"type":20},84,[23],"Comparison and evaluation of the difference in clinical efficacy of electroacupuncture combined with surrounding acupuncture and sham electroacupuncture groups and control group (ice compress combined with brake rest group) in the treatment of ALAS by means of musculoskeletal ultrasound technique.",[26],"2023-12-13",{"date":573,"type":38},"2023-12-27",{"date":575,"type":38},"2023-11-23",{"date":577,"type":20},"2026-11-22",{"name":166,"class":45},{"id":580,"slug":581,"hasResults":11,"nctId":582,"briefTitle":583,"officialTitle":584,"acronym":4,"eligibilityCriteria":585,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":124,"enrollmentInfo":586,"targetDuration":4,"studyType":588,"phases":4,"briefSummary":589,"conditions":590,"keywords":594,"overallStatus":186,"whyStopped":4,"lastUpdateSubmitDate":602,"lastUpdatePostDateStruct":603,"startDateStruct":605,"completionDateStruct":607,"leadSponsor":609,"locationsCount":46},"100466701","electroacupuncture-pain-treatment-mechanical-hyperalgesia-quality-of-life--expression-of-mu-b-cells-in-fibromyalgia-100466701","NCT05357157","Electroacupuncture Pain Treatment, Mechanical Hyperalgesia, Quality of Life & Expression of Mu+ B Cells in Fibromyalgia","Effect of Electroacupuncture Treatment on Pain, Mechanical Hyperalgesia, Quality of Life and Expression of Mu+ B Cells in Patients With Fibromyalgia: A Prospective Observational Study","Inclusion Criteria:\n\n* Patient's consent\n* Age \\>18 years old\n* Patients with diagnosed fibromyalgia from rheumatologists\n* Widespread pain more than 6 months\n* In case of drug therapy, it should be taken at least one month before the beginning of the session and remain stable till the end of the study\n\nExclusion Criteria:\n\n* Deep depression\n* Biological agent use ( TNF inhibitors)\n* Heamatological diseases\n* Systemic Infections\n* pregnancy\n* electroacupuncture contraindications (epilepsy, pacemaker\u002F implantable cardioverter defibrillator (ICD)",{"count":587,"type":20},80,"OBSERVATIONAL","Fibromyalgia (FM) is a complex, multifactorial syndrome characterized by widespread chronic pain with hyperal- gesia and allodynia and a constellation of somatic and psychological manifestations, including fatigue, sleep dis- orders, depression, anxiety, gastrointestinal and cognitive disorders. FM is now recognized as one of the most common chronic pain conditions and its management remains a challenge for patients and healthcare profes- sionals. The fact that FM is associated with chronic pain without any obvious peripheral tissue damage has given rise to the concept of nociplastic pain with evidence of dysfunction in mono-aminergic neurotransmission, lead- ing to elevated levels of excitatory neurotransmitters and decreased levels of serotonin and norepinephrine in the spinal cord at the level of descending anti-nociceptive pathways. Additionally, dopamine dysregulation and altered activity of endogenous cerebral opioids have been observed in FM.\n\nRecent European guidelines on FM treatment emphasize that there should be a comprehensive assessment of patient's pain, function and psychosocial context. It is recognized that there are profound and fundamental problems associated with the pain assessment tools in common use, as most of these represent an attempt to reduce a multidimensional experience to a coarse unidimensional measure. Use of multiple tools for sub- jective and objective assessment of pain may reflect more accurately patient's pain experience. Furthermore, tracing a biologic pain marker in FM patients would facilitate both the initial assessment of pain and the re- sponse to treatment. Management of pain in FM patients should focus first on non-pharmacological modalities. Acupuncture therapy is an effective and safe treatment and exerts its analgesic effect through activation of pe- ripheral and central pain control systems with the release of β-endorphins, enkephalins, dynorphins, serotonin, norepinephrine, γ-aminobutyric acid or ATP. The aim of our study is to assess initially reported pain and evaluate the effectiveness of electroacupuncture (with or without diet modifications) on the \"whole experience of pain\" in FM patients in a multimodel assessment frame.",[591,26,592,593],"Fibromyalgia","Acupuncture","Hyperalgesia",[591,595,26,592,596,597,593,598,599,600,601],"Chronic Pain","Palmitoylethanolamide","MOR-Positive B Cell","Quality of life","Pressure Algometry","Anti-inflammatory Nutrition","Depression","2022-10-23",{"date":604,"type":38},"2022-10-26",{"date":606,"type":38},"2022-05-31",{"date":608,"type":20},"2026-12-01",{"name":610,"class":45},"University of Crete"]